A rapid and sensitive HPLC-APCI-MS/MS method determination of fluticasone in human plasma: Application for a bioequivalency study in nasal spray formulations

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 38-43

  Byrro, Ricardo Martins Duarte ^a,b   César, Isabela Costa ^a,b   de Santana e Silva Cardoso, Fabiana Fernandes ^a   Mundim, Iram Moreira ^a   Teixeira, Leonardo de Souza ^a   Bonfim, Ricardo Rodrigues ^a   Gomes, Sandro Antônio ^a   Pianetti, Gerson Antônio ^b  

^a Instituto de Ciencias Farmaceuticas   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bioequivalence; Fluticasone; HPLC APCI MS MS; Nasal spray; Plasma

Indexed keywords

ACETONITRILE; BECLOMETASONE; FLUTICASONE; FORMIC ACID; NOSE SPRAY;

ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG STRUCTURE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ANDROSTADIENES; ATMOSPHERIC PRESSURE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; NASAL SPRAYS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 84856097841     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.018     Document Type: Article

References (14)

1. Callejas S.L., Biddlecombe R.A., Jones A.E., Joyce K.B., Pereira A.I., Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 1998, 718:243-250.
2. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am. J. Rhinol. 2007, 21:70-79.
3. Fuller R., Johnson M., Bye A. Fluticasone propionate - an update on preclinical and clinical experience. Respir. Med. 1995, 89:3-18.
4. Brutsche M.H., Brutsche I.C., Munavvar M., Langley S.J., Masterson C.M., Daley-Yates P.T., Brown R., Custovic A., A.Woodcock T. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000, 356:556-561.
5. Waddell A.N., Patel S.K., Toma A.G., Maw A.R. Intranasal steroid sprays in the treatment of rhinitis: is one better than another?. J. Laryngol. Otol. 2003, 117:843-845.
6. Daley-Yates P.T., Baker R.C. Systemic bioavailability of futicasone propionate administered as nasal drops and aqueous nasal spray formulations. Br. J. Clin. Pharmacol. 2001, 51:103-105.
7. Daley-Yates P.T., Price A.C., Sisson J.R., Pereira A., Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol. 2001, 51:400-409.
8. Jeal W., Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997, 53:257-280.
9. Daley-Yates P.T., Kunka R.L., Yin Y., Andrews S.M.S., Callejas C. Ng Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004, 60:265-268.
10. Li Y.N.B., Tattam B.N., Brown K.F.J., Seale P. A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. J. Pharm. Biomed. Anal. 1997, 16:447-452.
11. Laugher L., Noctor T.G., Barrow A., Oxford J.M., Phillips T. An improved method for the determination of fluticasone propionate in human plasma. J. Pharm. Biomed. Anal. 1999, 21:749-758.
12. Krishnaswami S., Mollmann H., Derendorf H., Hochhaus G. A sensitive LC-MS:MS method for the quantification of fluticasone propionate in human plasma. J. Pharm. Biomed. Anal. 2000, 22:23-129.
13. Food and Drug Administration FDA Guidance for Industry: Bioanalytical Method Validation 2001, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
14. Hopfgartner G., Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom. Rev. 2003, 22:195-214.